Make your one-time, tribute, or recurring online gift to support brain tumour patient programs and research today: Donate
Dr. Sabine Mai
Manitoba Institute of Cell Biology, Winnipeg, MB
The proposed study focuses on ependymoma, a childhood brain tumour. At diagnosis, it is not possible to know which child will respond to treatment and which child will recur, i.e. if prognosis is favourable or non-favourable. We have developed quantitative tools that may allow for the distinction of good and poor responders at diagnosis.
These tools involve three-dimensional (3D) imaging of telomeres. Telomeres are the ends of chromosomes; they protect the chromosomes from damage and prevent recombination and fusion with other chromosomes (Mai, 2010). Telomere dysfunction therefore is associated with genomic instability and found in many cancers (Mai and Garini, 2006; Mai, 2010).
The data obtained in this study are quantitatively measured, and the output is expected to be a 3D nuclear telomeric profile of each child’s tumour, indicative of favourable or non-favourable disease and will, in the near future, enable for the first time a choice for specific treatments for each child’s ependymoma.
When John Hatcher laces up his running shoes on Saturday, October 2, 2016 he joins over a dozen of his family members and friends for the Newfoundland & Labrador Brain Tumour Walk as team Astro-Blasters. "It's our first year," he explains, "and knowing first-hand how little is said or recognized about brain tumours, we want to help any way we can." Over the past eight years, John has undergone radiation, multiple brain surgeries and, now, chemotherapy for the tumour.Learn more
This colourful book tells the story of a little girl and her journey with a brain tumour...Learn more
For Theresa Acchione Parkinson, it’s been 15 years since her father passed away from glioblastoma brain cancer. And while Theresa...Learn more